| CFC increase . | OR (95% CI) . | P-value . |
|---|---|---|
| Baseline CFC groups | <0.01 | |
| Severely reduced CFC vs. moderately reduced CFC | 4.84 (2.12–11.09) | |
| Severely reduced CFC vs. minimally reduced CFC | 5.77 (2.20–15.16) | |
| Moderately reduced CFC vs. minimally reduced CFC | 1.19 (0.67–2.13) | |
| Demographics | ||
| Gender (male vs. female) | 0.43 (0.17–1.10) | 0.08 |
| Age (years) | 0.99 (0.96–1.02) | 0.37 |
| BMI | 1.00 (0.94–1.07) | 0.99 |
| Cardiovascular risk factors | ||
| Hypertension | 1.37 (0.75–2.48) | 0.30 |
| Hypercholesterolaemia | 1.18 (0.61–1.84) | 0.83 |
| Diabetes mellitus | 0.69 (0.38–1.25) | 0.22 |
| Family history of CAD | 0.96 (0.52–1.64) | 0.87 |
| Smoking | 1.55 (0.79–3.08) | 0.21 |
| Cardiac history | ||
| History of MI | 0.56 (0.31–1.00) | 0.05 |
| History of PCI | 0.98 (0.51–1.89) | 0.95 |
| History of CABG | 0.48 (0.21–1.08) | 0.07 |
| Medication | ||
| Aspirin | 1.07 (0.34–3.33) | 0.91 |
| β-Blocker | 1.11 (0.54–2.26) | 0.78 |
| ACE inhibitor/ARB | 0.72 (0.40–1.3) | 0.28 |
| Statin | 0.76 (0.31–1.85) | 0.54 |
| Calcium channel blocker | 0.95 (0.52–1.75) | 0.87 |
| Revascularization | ||
| Surgical revascularization | 0.86 (0.33–2.29) | 0.77 |
| CFC increase . | OR (95% CI) . | P-value . |
|---|---|---|
| Baseline CFC groups | <0.01 | |
| Severely reduced CFC vs. moderately reduced CFC | 4.84 (2.12–11.09) | |
| Severely reduced CFC vs. minimally reduced CFC | 5.77 (2.20–15.16) | |
| Moderately reduced CFC vs. minimally reduced CFC | 1.19 (0.67–2.13) | |
| Demographics | ||
| Gender (male vs. female) | 0.43 (0.17–1.10) | 0.08 |
| Age (years) | 0.99 (0.96–1.02) | 0.37 |
| BMI | 1.00 (0.94–1.07) | 0.99 |
| Cardiovascular risk factors | ||
| Hypertension | 1.37 (0.75–2.48) | 0.30 |
| Hypercholesterolaemia | 1.18 (0.61–1.84) | 0.83 |
| Diabetes mellitus | 0.69 (0.38–1.25) | 0.22 |
| Family history of CAD | 0.96 (0.52–1.64) | 0.87 |
| Smoking | 1.55 (0.79–3.08) | 0.21 |
| Cardiac history | ||
| History of MI | 0.56 (0.31–1.00) | 0.05 |
| History of PCI | 0.98 (0.51–1.89) | 0.95 |
| History of CABG | 0.48 (0.21–1.08) | 0.07 |
| Medication | ||
| Aspirin | 1.07 (0.34–3.33) | 0.91 |
| β-Blocker | 1.11 (0.54–2.26) | 0.78 |
| ACE inhibitor/ARB | 0.72 (0.40–1.3) | 0.28 |
| Statin | 0.76 (0.31–1.85) | 0.54 |
| Calcium channel blocker | 0.95 (0.52–1.75) | 0.87 |
| Revascularization | ||
| Surgical revascularization | 0.86 (0.33–2.29) | 0.77 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CFC, coronary flow capacity; LAD, left anterior descending coronary artery; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
| CFC increase . | OR (95% CI) . | P-value . |
|---|---|---|
| Baseline CFC groups | <0.01 | |
| Severely reduced CFC vs. moderately reduced CFC | 4.84 (2.12–11.09) | |
| Severely reduced CFC vs. minimally reduced CFC | 5.77 (2.20–15.16) | |
| Moderately reduced CFC vs. minimally reduced CFC | 1.19 (0.67–2.13) | |
| Demographics | ||
| Gender (male vs. female) | 0.43 (0.17–1.10) | 0.08 |
| Age (years) | 0.99 (0.96–1.02) | 0.37 |
| BMI | 1.00 (0.94–1.07) | 0.99 |
| Cardiovascular risk factors | ||
| Hypertension | 1.37 (0.75–2.48) | 0.30 |
| Hypercholesterolaemia | 1.18 (0.61–1.84) | 0.83 |
| Diabetes mellitus | 0.69 (0.38–1.25) | 0.22 |
| Family history of CAD | 0.96 (0.52–1.64) | 0.87 |
| Smoking | 1.55 (0.79–3.08) | 0.21 |
| Cardiac history | ||
| History of MI | 0.56 (0.31–1.00) | 0.05 |
| History of PCI | 0.98 (0.51–1.89) | 0.95 |
| History of CABG | 0.48 (0.21–1.08) | 0.07 |
| Medication | ||
| Aspirin | 1.07 (0.34–3.33) | 0.91 |
| β-Blocker | 1.11 (0.54–2.26) | 0.78 |
| ACE inhibitor/ARB | 0.72 (0.40–1.3) | 0.28 |
| Statin | 0.76 (0.31–1.85) | 0.54 |
| Calcium channel blocker | 0.95 (0.52–1.75) | 0.87 |
| Revascularization | ||
| Surgical revascularization | 0.86 (0.33–2.29) | 0.77 |
| CFC increase . | OR (95% CI) . | P-value . |
|---|---|---|
| Baseline CFC groups | <0.01 | |
| Severely reduced CFC vs. moderately reduced CFC | 4.84 (2.12–11.09) | |
| Severely reduced CFC vs. minimally reduced CFC | 5.77 (2.20–15.16) | |
| Moderately reduced CFC vs. minimally reduced CFC | 1.19 (0.67–2.13) | |
| Demographics | ||
| Gender (male vs. female) | 0.43 (0.17–1.10) | 0.08 |
| Age (years) | 0.99 (0.96–1.02) | 0.37 |
| BMI | 1.00 (0.94–1.07) | 0.99 |
| Cardiovascular risk factors | ||
| Hypertension | 1.37 (0.75–2.48) | 0.30 |
| Hypercholesterolaemia | 1.18 (0.61–1.84) | 0.83 |
| Diabetes mellitus | 0.69 (0.38–1.25) | 0.22 |
| Family history of CAD | 0.96 (0.52–1.64) | 0.87 |
| Smoking | 1.55 (0.79–3.08) | 0.21 |
| Cardiac history | ||
| History of MI | 0.56 (0.31–1.00) | 0.05 |
| History of PCI | 0.98 (0.51–1.89) | 0.95 |
| History of CABG | 0.48 (0.21–1.08) | 0.07 |
| Medication | ||
| Aspirin | 1.07 (0.34–3.33) | 0.91 |
| β-Blocker | 1.11 (0.54–2.26) | 0.78 |
| ACE inhibitor/ARB | 0.72 (0.40–1.3) | 0.28 |
| Statin | 0.76 (0.31–1.85) | 0.54 |
| Calcium channel blocker | 0.95 (0.52–1.75) | 0.87 |
| Revascularization | ||
| Surgical revascularization | 0.86 (0.33–2.29) | 0.77 |
ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass graft; CAD, coronary artery disease; CFC, coronary flow capacity; LAD, left anterior descending coronary artery; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
